MSI2 and myeloid leukemia: In a case study built using this platform, Hattori et al. (114) studied the aberrant BCAA (branched-chain amino acids) metabolism activation by MSI2 (Musashi2)-BCAT1 axis which they reported to drive myeloid leukemia progression.